dap1 Antibody

What is DAP1 and what are its primary functions in cellular pathways?

DAP1 (Death-associated protein 1) is a basic proline-rich 15kDa protein that functions as a positive mediator of programmed cell death induced by interferon-gamma . Recent research has expanded our understanding of DAP1's multifunctional role in cellular processes:

• Acts as a negative regulator of autophagy

• Functions as a key regulator through PERK-eIF2α-dependent pathways in the induction of apoptosis

• Serves as a ribosome-binding protein involved in ribosome hibernation, preventing mRNA translation

• Associates with eiF5a at the polypeptide exit tunnel of the ribosome

• In yeast systems, interacts with cytochrome P450s and functions in the synthesis of certain compounds like astaxanthin and ergosterol

DAP1 has been implicated in multiple cellular signaling networks, with its regulatory functions varying depending on cell type and physiological context.

The choice between monoclonal and polyclonal DAP1 antibodies depends on experimental requirements:

Polyclonal DAP1 Antibodies:

• Recognize multiple epitopes on DAP1

• Generally provide higher sensitivity due to binding multiple sites

• Show broader reactivity across species (typically human, mouse, rat)

• May have higher batch-to-batch variability

• Examples: Boster Bio A02756-1, Proteintech 10160-1-AP

Monoclonal DAP1 Antibodies:

• Target a single epitope with high specificity

• Provide consistent results with minimal batch-to-batch variation

• Particularly valuable for detecting specific conformations or domains

• May be less sensitive than polyclonals in some applications

• Examples: Abcam ab32056 [E59], Santa Cruz sc-376754 (C-8)

For critical quantitative studies where reproducibility is paramount, monoclonal antibodies like the recombinant rabbit monoclonal [E59] may offer advantages . For applications requiring higher sensitivity or detection across multiple species, polyclonal antibodies may be preferable.

How can DAP1 antibody specificity be validated in experimental systems?

Comprehensive validation of DAP1 antibodies should employ multiple complementary approaches:

• Genetic Controls:

  • Compare antibody reactivity in wild-type vs. DAP1 knockout/knockdown systems

  • Use CRISPR/Cas9 knockout systems (available as plasmids)

  • Employ siRNA or shRNA-mediated knockdown of DAP1

• Peptide Competition Assays:

  • Pre-incubate antibody with immunizing peptide (e.g., the 19 amino acid peptide near the carboxy terminus used for many commercial antibodies)

  • Observe elimination or reduction of specific signal

• Multi-antibody Verification:

  • Compare results from antibodies targeting different DAP1 epitopes

  • Test both N-terminal and C-terminal targeting antibodies

• Recombinant Protein Controls:

  • Use purified recombinant DAP1 as positive control

  • Compare migration pattern with endogenous protein

• Cross-species Reactivity:

  • Verify consistent detection pattern across relevant species

  • Align epitope sequences across species to predict cross-reactivity

The observed molecular weight of DAP1 may vary (~15 kDa theoretical vs. ~68 kDa observed in some systems) , so validation across multiple techniques is essential for confirming specificity.

What are the optimal protocols for co-immunoprecipitation to study DAP1 protein interactions?

Co-immunoprecipitation (co-IP) is valuable for investigating DAP1 interactions with binding partners. Based on published methodologies , an optimized protocol includes:

Sample Preparation:

• Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, supplemented with protease and phosphatase inhibitors

• Centrifuge at 15,000g for 15 min at 4°C to collect solubilized extracts

Immunoprecipitation:

• Incubate 100-200 μg protein extract with 1-5 μg DAP1 antibody at 4°C for 3-4 hours

• Add protein G-Sepharose beads and incubate for additional 1 hour

• Centrifuge briefly (1 min) at 4°C to collect immunocomplexes

• Wash immunocomplexes 3-4 times with lysis buffer

Analysis:

• Dissolve proteins in SDS sample buffer and separate by SDS-PAGE

• Transfer to PVDF membrane

• Probe with antibodies against suspected interaction partners

Critical Considerations:

• Include appropriate controls (IgG control, input sample)

• For studying DAP1 interactions with P450 systems, more stringent washing conditions may be needed

• For capturing transient interactions, consider chemical crosslinking prior to lysis

• Dilution ratio of 1:50 has been reported effective for immunoprecipitation with some DAP1 antibodies

This approach has successfully demonstrated DAP1's interactions with various proteins, including P450s in yeast systems and components of autophagy regulation pathways.

How should experiments be designed to investigate DAP1's role in autophagy regulation?

DAP1 functions as a negative regulator of autophagy , requiring specialized experimental design for accurate assessment of its function:

Key Experimental Approaches:

• Autophagy Flux Assessment:

  • Monitor LC3B-I to LC3B-II conversion by immunoblotting with and without lysosomal inhibitors (e.g., bafilomycin A1)

  • Visualize LC3B puncta formation using immunofluorescence with anti-LC3B antibody (D11; 1:200 dilution)

  • Assess SQSTM1/p62 degradation as an autophagy substrate (using D10E10 antibody; 1:400 dilution)

• DAP1 Modulation Strategies:

  • Use DAP1 CRISPR/Cas9 knockout systems

  • Apply transient siRNA knockdown

  • Create DAP1 phosphomimetic mutants (S3 and S51 sites are critical for mTOR regulation)

• Nutrient Deprivation Response:

  • Compare DAP1 phosphorylation status under rich vs. starvation conditions

  • Monitor autophagy markers in response to DAP1 manipulation during starvation

• Imaging Protocol:

  • Fix cells and incubate with primary antibodies in 0.4% BSA-PBS buffer overnight at 4°C

  • Use appropriate secondary antibodies (e.g., DyLight 488-conjugated anti-mouse or Cy3-conjugated anti-rabbit)

  • Counterstain with DAPI and visualize using confocal microscopy

• Quantification Approaches:

  • Count LC3B puncta per cell across multiple fields

  • Measure LC3B-II/LC3B-I ratio by densitometry

  • Quantify SQSTM1/p62 levels normalized to loading control

By implementing these approaches, researchers can effectively assess how DAP1 functions in autophagy regulation pathways in different cellular contexts.

What are the technical considerations for using DAP1 antibodies in immunofluorescence and immunohistochemistry?

Successful detection of DAP1 by immunofluorescence (IF) and immunohistochemistry (IHC) requires optimization of several parameters:

Fixation and Antigen Retrieval:

• For paraffin-embedded tissues: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is effective

• For cells: 4% paraformaldehyde fixation followed by 0.1% Triton X-100 permeabilization

• For enzymatic antigen retrieval: IHC enzyme antigen retrieval reagent treatment for 15 mins

Blocking and Antibody Incubation:

• Block with 10% goat serum to minimize non-specific binding

• Primary antibody concentrations:

  • Polyclonal antibodies: 2-5 μg/mL, incubate overnight at 4°C

  • Monoclonal antibodies: Follow manufacturer's recommended dilution

• Secondary antibody options:

  • DyLight 488-conjugated anti-rabbit IgG (1:100 dilution)

  • Cy3-conjugated anti-rabbit antibody

  • Directly conjugated antibodies (e.g., mFluor Violet 610 SE) are available

Detection Systems:

• For IHC: Biotinylated secondary antibodies with Strepavidin-Biotin-Complex (SABC) and DAB as chromogen

• For IF: Appropriate fluorophore-conjugated secondary antibodies matched to microscopy filter sets

• Counterstain nuclei with DAPI

Image Acquisition:

• For IF: Confocal microscopy provides optimal resolution for subcellular localization

• Acquire Z-stacks to ensure complete visualization of DAP1 distribution

• Capture images using consistent exposure settings across experimental groups

Controls and Validation:

• Include peptide competition controls to confirm specificity

• Use DAP1 knockout/knockdown samples as negative controls

• Compare localizations observed with antibodies targeting different epitopes

These technical considerations will help ensure specific and reproducible detection of DAP1 in tissue and cellular samples.

How can inconsistent results with DAP1 antibodies be troubleshooted across different applications?

When encountering inconsistent results with DAP1 antibodies, systematic troubleshooting is essential:

Western Blotting Inconsistencies:

• Variable molecular weight: DAP1 may appear at ~15 kDa (theoretical) or ~68 kDa in some systems . Verify with multiple antibodies targeting different epitopes.

• Weak signal: Increase protein loading (30-50 μg), optimize antibody concentration, or use enhanced chemiluminescence detection systems like SuperSignal (Pierce) .

• Multiple bands: Test reducing vs. non-reducing conditions; DAP1 may form complexes that resolve differently.

Immunoprecipitation Failures:

• Poor pull-down efficiency: Increase antibody amount (up to 5 μg) or extend incubation time (overnight at 4°C).

• Non-specific interactions: Use more stringent washing conditions (higher salt concentration).

• No co-immunoprecipitation detected: Consider stabilizing interactions with crosslinking reagents.

Immunofluorescence Issues:

• High background: Improve blocking (5% BSA or 10% serum from secondary antibody species), increase washing steps.

• No signal: Optimize antigen retrieval method; test multiple fixation protocols.

• Unexpected localization: Verify with multiple antibodies and compare to published literature.

Flow Cytometry Challenges:

• Poor separation: Use True-stain monocyte Blocker for samples containing myeloid cells .

• Non-specific binding: Apply FcR blocking (10% homologous serum or commercial Fc block) .

General Recommendations:

• Test multiple antibody lots if possible

• Validate antibodies in positive and negative control samples

• Adjust protocols based on specific cell types/tissues being studied

• Compare results across multiple detection methods

Careful optimization and validation will help ensure consistent and reliable results across different applications.

What approaches can be used to study DAP1 phosphorylation and its impact on protein function?

DAP1 phosphorylation, particularly at serine residues S3 and S51 by mTOR, critically regulates its function in autophagy . To investigate this regulatory mechanism:

Phosphorylation Detection Methods:

• Phospho-specific Antibodies:

  • Generate or obtain antibodies specific to phosphorylated S3 and S51 sites

  • Validate using phosphatase treatment controls

• Phosphorylation Shift Assays:

  • Use Phos-tag™ SDS-PAGE to separate phosphorylated from non-phosphorylated forms

  • Compare migration patterns before/after phosphatase treatment

• Mass Spectrometry:

  • Immunoprecipitate DAP1 and analyze by LC-MS/MS

  • Map phosphorylation sites and quantify relative abundance

Functional Analysis of Phosphorylation:

• Phosphomimetic/Phospho-dead Mutants:

  • Generate S3E/S51E (phosphomimetic) and S3A/S51A (phospho-dead) mutants

  • Express in DAP1-knockout backgrounds to assess functional consequences

• mTOR Inhibition Studies:

  • Use rapamycin or Torin1 to inhibit mTOR activity

  • Monitor changes in DAP1 phosphorylation and autophagy markers

• Nutrient Deprivation Experiments:

  • Compare rich vs. starvation conditions to manipulate mTOR activity

  • Assess changes in DAP1 phosphorylation status

• Protein Interaction Analysis:

  • Compare binding partners of phosphorylated vs. non-phosphorylated DAP1

  • Use BioID or proximity ligation assays to identify context-specific interactions

These approaches will provide insights into how phosphorylation regulates DAP1's role in autophagy and other cellular processes, with implications for understanding disease mechanisms related to autophagy dysregulation.

What are the best strategies for developing a two-antibody detection system for DAP1 in ELISA and other quantitative assays?

Developing a robust two-antibody detection system for DAP1 requires careful selection of antibodies targeting distinct epitopes. Based on approaches used for other proteins , the following strategy is recommended:

Antibody Pair Selection:

• Epitope Mapping:

  • Choose antibodies recognizing spatially distant epitopes on DAP1

  • Select antibodies raised against different regions (N-terminal vs. C-terminal)

  • Consider using the epitope-directed monoclonal antibody production approach described by Liew et al.

• Antibody Format Optimization:

  • Test combinations of monoclonal and polyclonal antibodies

  • Evaluate different host species to minimize cross-reactivity

  • Compare direct detection (conjugated primary) vs. indirect detection systems

ELISA Development:

• Sandwich ELISA Configuration:

  • Capture antibody: Coat plates with 1-5 μg/mL antibody in carbonate buffer (pH 9.6)

  • Detection antibody: Biotinylate or directly conjugate with enzyme (HRP/AP)

  • Consider using novel platforms like DEXT microplates for assay miniaturization

• Optimization Parameters:

  • Test multiple antibody pairs in both orientations (each as capture/detector)

  • Determine optimal blocking conditions (typically 1-5% BSA or non-fat milk)

  • Establish standard curves using recombinant DAP1

• Validation:

  • Assess specificity using samples with DAP1 knockdown/knockout

  • Determine limit of detection and quantification

  • Evaluate precision (intra/inter-assay CV%)

Example Workflow Based on Published Methods:

• Screen 12×12 capture/detector mAb combinations by ELISA using recombinant DAP1

• Identify pairs with highest signal response and signal-to-noise ratio

• Evaluate self-pairing possibilities if DAP1 forms dimers

• Validate in biological samples with varying DAP1 expression levels

This systematic approach will facilitate development of sensitive and specific quantitative assays for DAP1 detection in research and potentially diagnostic applications.

How should experiments be designed to investigate DAP1's role in interferon-gamma-induced cell death pathways?

DAP1 was originally identified as a positive mediator of programmed cell death induced by interferon-gamma . To investigate this function:

Experimental Design Strategy:

• Cell Death Assessment Methods:

  • Annexin V/PI staining and flow cytometry to distinguish apoptotic vs. necrotic death

  • Caspase activation assays (caspase-3/7, -8, -9) to determine apoptotic pathway involvement

  • TUNEL assay for DNA fragmentation detection

  • Live-cell imaging with appropriate probes to track cell death kinetics

• DAP1 Modulation Approaches:

  • Generate stable DAP1 knockdown cell lines using shRNA

  • Create transient knockdown using siRNA

  • Establish CRISPR/Cas9 knockout systems

  • Develop inducible expression systems for controlled restoration of DAP1 function

• Interferon-gamma Treatment Parameters:

  • Dose-response studies (typically 10-1000 U/mL)

  • Time-course experiments (6, 12, 24, 48 hours)

  • Combined treatment with sensitizing agents or inhibitors of specific death pathways

• Mechanistic Investigations:

  • Examine DAP1's effect on PERK-eIF2α pathway activation

  • Assess mitochondrial outer membrane permeabilization (Bax/Bak activation)

  • Monitor conformational changes in Bax/Bak using conformation-specific antibodies

  • Evaluate LC3B and SQSTM1/p62 to determine autophagy's role in the death process

• Protein-Protein Interaction Studies:

  • Immunoprecipitate DAP1 before/after interferon-gamma treatment

  • Identify differential binding partners using mass spectrometry

  • Confirm key interactions using reciprocal co-IP or proximity ligation assay

• In vivo Relevance:

  • Examine DAP1 expression in tissues from interferon-gamma-treated animal models

  • Correlate DAP1 levels with markers of cell death in relevant disease models

This comprehensive approach will help elucidate DAP1's precise role in interferon-gamma-induced death pathways and potentially identify novel therapeutic targets for diseases involving dysregulated cell death.

What are the recent advances in understanding DAP1's role in ribosome hibernation and translational control?

Recent research has revealed DAP1's unexpected function in ribosome hibernation, a process where ribosomes are stabilized in an inactive state and preserved from proteasomal degradation . This represents an emerging area of DAP1 biology with significant implications:

Key Research Findings:

• Mechanism of Action:

  • DAP1 associates with eiF5a (EIF5A and EIF5A2) at the polypeptide exit tunnel of ribosomes

  • This interaction prevents mRNA translation, effectively silencing protein synthesis

  • DAP1 is particularly important in ribosome hibernation in mature oocytes

• Developmental Context:

  • Ribosomes produced during oogenesis are stored and translationally repressed in oocytes and early embryos

  • DAP1 likely plays a critical role in preserving these ribosomes for later activation

• Relationship to Other DAP1 Functions:

  • The connection between DAP1's roles in autophagy regulation, apoptosis, and translational control remains to be fully elucidated

  • These functions may represent context-dependent responses to different cellular stresses

Research Methodologies:

Recent studies investigating DAP1's role in translational control have employed:

• Ribosome profiling to assess global translation rates

• Polysome profiling to examine ribosome association with mRNAs

• Cryo-EM structural studies of DAP1-ribosome complexes

• Genetic models with conditional DAP1 ablation in specific developmental contexts

Future Research Directions:

• Identification of mRNAs specifically regulated by DAP1-mediated translational control

• Characterization of factors that regulate DAP1's association with ribosomes

• Investigation of DAP1's role in stress granule formation and regulation

• Exploration of DAP1 function in developmental contexts requiring precise translational control

This emerging research area connects DAP1 to fundamental processes of translational regulation with implications for understanding both normal development and disease states.

What methodological approaches can be used to study DAP1's interactions with cytochrome P450 systems?

DAP1's role in regulating cytochrome P450 (P450) systems, particularly in yeast models, represents an important area for investigation . Based on current research, the following methodological approaches are recommended:

Protein-Protein Interaction Analysis:

• Co-immunoprecipitation (Co-IP):

  • Optimize lysis conditions (typically containing 1% digitonin or CHAPS detergent)

  • Use antibodies against DAP1 to pull down associated P450s

  • Perform reciprocal experiments using P450-specific antibodies

  • Include appropriate controls (IgG, lysate input)

• Proximity-Based Methods:

  • BioID approach: Express DAP1-BirA* fusion to biotinylate proximal proteins

  • APEX2 proximity labeling with DAP1-APEX2 fusion

  • Split-GFP complementation to visualize direct interactions

• Biophysical Techniques:

  • Surface plasmon resonance to measure binding kinetics

  • Microscale thermophoresis for quantitative interaction analysis

  • Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

Functional Assessment:

• Enzymatic Activity Assays:

  • Measure P450 activities (e.g., Cyp51, Cyp61, CrtS) in the presence/absence of DAP1

  • Compare wild-type vs. DAP1 mutant effects on P450 catalytic efficiency

  • Assess heme incorporation into P450s with altered DAP1 levels

• Metabolite Analysis:

  • Quantify end products (e.g., ergosterol, astaxanthin) using HPLC or LC-MS

  • Measure accumulation of intermediate metabolites to identify rate-limiting steps

  • Perform isotope labeling studies to track metabolic flux

• Gene Expression Analysis:

  • Compare transcript levels of P450 genes in wild-type vs. DAP1 mutants

  • Assess protein levels of P450s with varying DAP1 expression

  • Investigate compensatory transcriptional responses

System-Specific Considerations:

For studying DAP1-P450 interactions in specific systems like X. dendrorhous (as described in search result ):

• Generate tagged DAP1 variants (e.g., DAP1.FLAG) for efficient pulldown

• Create specific gene deletions (e.g., Δdap1) to assess functional consequences

• Employ heterologous expression systems to reconstitute interactions in controllable contexts

These methodological approaches will help elucidate DAP1's role in regulating P450 systems across different organisms and biological contexts.

How can researchers effectively validate epitope-specific DAP1 antibodies for specialized applications?

The epitope-directed monoclonal antibody production method described by Liew et al. offers insights into effective validation strategies for epitope-specific DAP1 antibodies:

Comprehensive Validation Framework:

• Epitope Mapping and Confirmation:

  • Identify precise epitope sequences using peptide arrays or alanine scanning mutagenesis

  • Confirm epitope accessibility in native protein using structural modeling

  • Generate epitope-swapped mutants for cross-validation

  • Validate using peptide competition assays with synthesized epitope peptides

• Cross-Species Reactivity Assessment:

  • Align epitope sequences across species to predict reactivity

  • Test antibodies against recombinant DAP1 from multiple species

  • Verify consistent detection patterns in cellular/tissue samples from different species

  • Generate species-specific negative controls using CRISPR knockout systems

• Multi-Application Validation:

  • Test each antibody systematically across all intended applications (WB, IP, IHC, IF, FC)

  • Establish optimal working conditions for each application

  • Create validation matrices documenting performance across applications

  • Compare results with commercially available antibodies targeting the same epitope

• Affinity and Specificity Quantification:

  • Measure antibody affinity (KD) using surface plasmon resonance or bio-layer interferometry

  • Assess cross-reactivity with closely related proteins

  • Test specificity in complex biological samples with varying DAP1 expression levels

  • Verify performance in DAP1 knockout/knockdown systems

Specialized Validation for Phospho-Specific Antibodies:

• Test with phosphatase-treated samples as negative controls

• Validate using phosphomimetic vs. phospho-dead DAP1 mutants

• Confirm phosphorylation-dependent detection using in vitro kinase assays

• Verify physiological relevance using stimuli known to alter DAP1 phosphorylation

Documentation and Reporting:

• Document all validation steps with appropriate controls

• Report antibody performance metrics quantitatively

• Provide detailed protocols for optimal use in each application

• Share validation data in repositories like Antibodypedia or CiteAb